focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,166.00
Bid: 12,132.00
Ask: 12,136.00
Change: -6.00 (-0.05%)
Spread: 4.00 (0.033%)
Open: 12,180.00
High: 12,198.00
Low: 12,076.00
Prev. Close: 12,172.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS SUMMARY: UBS Upgrades AstraZeneca To Neutral

Mon, 30th Nov 2020 09:49

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

----------

FTSE 100

----------

UBS RAISES ASTRAZENECA TO 'NEUTRAL' (SELL) - PRICE TARGET 7,500 (7,300) PENCE

----------

BARCLAYS RAISES UNILEVER PRICE TARGET TO 5,500 (5,420) PENCE - 'OVERWEIGHT'

----------

UBS RAISES MELROSE INDUSTRIES PRICE TARGET TO 185 (134) PENCE - 'BUY'

----------

MORGAN STANLEY RAISES WHITBREAD TARGET TO 3,000 (2,700) PENCE - 'EQUAL-WEIGHT'

----------

BARCLAYS RAISES SPIRAX-SARCO PRICE TARGET TO 9,925 (9,380) PENCE - 'EQUAL WEIGHT'

----------

RBC RAISES NEXT PRICE TARGET TO 7,000 (6,500) PENCE - 'SECTOR PERFORM'

----------

RBC RAISES ASSOCIATED BRITISH FOODS PRICE TARGET TO 2,300 (2,100) PENCE - 'OUTPERFORM'

----------

RBC RAISES ANTOFAGASTA PRICE TARGET TO 1,080 (780) PENCE - 'UNDERPERFORM'

----------

RBC RAISES RIO TINTO PRICE TARGET TO 5,900 (5,000) PENCE - 'SECTOR PERFORM'

----------

RBC RAISES BHP GROUP PRICE TARGET TO 2,400 (2,000) PENCE - 'OUTPERFORM'

----------

RBC RAISES GLENCORE PRICE TARGET TO 280 (240) PENCE - 'OUTPERFORM'

----------

RBC RAISES ANGLO AMERICAN PRICE TARGET TO 3,400 (2,400) PENCE - 'OUTPERFORM'

----------

GOLDMAN SACHS CUTS AVEVA GROUP PRICE TARGET TO 3,600 (4,011) PENCE - 'NEUTRAL'

----------

GOLDMAN SACHS RAISES STANDARD LIFE ABERDEEN PRICE TARGET TO 298 (260) PENCE - 'BUY'

----------

GOLDMAN SACHS RAISES SCHRODERS PRICE TARGET TO 2,465 (2,195) PENCE - 'SELL'

----------

JEFFERIES RAISES AVIVA PRICE TARGET TO 400 (350) PENCE - 'BUY'

----------

BANK OF AMERICA RAISES AVIVA PRICE TARGET TO 375 (360) PENCE - 'NEUTRAL'

----------

JPMORGAN RAISES OCADO PRICE TARGET TO 2,000 (1,800) PENCE - 'NEUTRAL'

----------

FTSE 250

----------

RBC RAISES DUNELM GROUP TO 'OUTPERFORM' ('SECTOR PERFORM') - TARGET 1,450 PENCE

----------

RBC RAISES MARKS & SPENCER PRICE TARGET TO 145 (120) PENCE - 'OUTPERFORM'

----------

MORGAN STANLEY RAISES BEAZLEY PRICE TARGET TO 390 (350) PENCE - 'EQUAL-WEIGHT'

----------

MORGAN STANLEY RAISES LANCASHIRE PRICE TARGET TO 1,065 (1,045) P - 'OVERWEIGHT'

----------

MORGAN STANLEY RAISES HISCOX PRICE TARGET TO 1450 (990) PENCE - 'OVERWEIGHT'

----------

BARCLAYS RAISES VESUVIUS PRICE TARGET TO 500 (400) PENCE - 'EQUAL WEIGHT'

----------

BARCLAYS CUTS CARNIVAL PRICE TARGET TO 1,725 (2,250) PENCE - 'OVERWEIGHT'

----------

GOLDMAN SACHS RAISES MAN GROUP PRICE TARGET TO 140 (135) PENCE - 'NEUTRAL'

----------

GOLDMAN SACHS RAISES ASHMORE GROUP PRICE TARGET TO 435 (420) PENCE - 'BUY'

----------

JPMORGAN CUTS BODYCOTE TO 'UNDERWEIGHT' ('NEUTRAL') - TARGET 635 (670) PENCE

----------

BARCLAYS RAISES BODYCOTE PRICE TARGET TO 715 (620) PENCE - 'EQUAL WEIGHT'

----------

JPMORGAN RAISES MITCHELLS & BUTLERS TARGET TO 360 (340) PENCE - 'OVERWEIGHT'

----------

BANK OF AMERICA RAISES BALFOUR BEATTY PRICE TARGET TO 350 (345) PENCE - 'BUY'

----------

OTHER MAIN MARKET AND AIM

----------

UBS RAISES KINGSPAN GROUP PRICE TARGET TO 60 (55) EUR - 'SELL'

----------

BERENBERG RAISES VICTORIA PRICE TARGET TO 770 (330) PENCE - 'BUY'

----------

BARCLAYS CUTS NEWRIVER REIT PRICE TARGET TO 72 (76) PENCE - 'EQUAL WEIGHT'

----------

RBC RAISES CENTRAL ASIA METALS TO 'OUTPERFORM' ('SECTOR PERFORM') - TARGET 270 (170) PENCE

----------

RBC RAISES ANGLO PACIFIC GROUP PRICE TARGET TO 205 (195) PENCE - 'OUTPERFORM'

----------

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
2 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth

(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data across the globe.

Read more
2 Apr 2024 10:25

AstraZeneca and Daiichi make US progress with latest licence approvals

(Alliance News) - AstraZeneca PLC on Tuesday noted significant progress for two of its clinical-stage treatments in the US.

Read more
2 Apr 2024 09:54

LONDON BROKER RATINGS: Bernstein starts AstraZeneca at 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
2 Apr 2024 09:09

LONDON MARKET OPEN: FTSE 100 up as oil majors and gold miners shine

(Alliance News) - Stock prices in London opened higher on Tuesday, in confident trade following the long Easter weekend, ahead of a UK manufacturing sector reading later in the morning.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
2 Apr 2024 07:08

US FDA gives green light for use of AstraZeneca's Voydeva

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

Read more
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.